ライフサイエンスコーパス: paraneoplastic syndrome

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 (18)F-FDG PET/CT in patients with suspected paraneoplastic syndrome.

2 malignancy in patients suspected of having a paraneoplastic syndrome.

3 n of the nervous system may be involved in a paraneoplastic syndrome.

4 (18)F-FDG PET/CT in patients with suspected paraneoplastic syndrome.

5 malignancy in patients suspected of having a paraneoplastic syndrome.

6 cally suspected neurologic and nonneurologic paraneoplastic syndromes.

7 ntly fatal malignancy and for the associated paraneoplastic syndromes.

8 oplasm in patients presenting with suspected paraneoplastic syndromes.

9 elevant pathways that lead to the associated paraneoplastic syndromes.

10 15 patients with cancer presented as classic paraneoplastic syndromes (5 limbic encephalitis, 1 paran

11 Paraneoplastic syndromes affecting the nervous system ar

12 ytotoxic CD8+ T cell in patients with the Hu paraneoplastic syndrome and suggest that SCLC may evade

13 93 individual patients suspected of having a paraneoplastic syndrome and who underwent (18)F-FDG PET

14 93 individual patients suspected of having a paraneoplastic syndrome and who underwent (18)F-FDG PET

15 stic neurological symptoms, 96 patients with paraneoplastic syndromes and 10 patients with non-cancer

16 nd toxic molecules to the internodal axon in paraneoplastic syndromes and demyelinating diseases.

17 "brain-testis-cancer" gene related to other paraneoplastic syndromes and tumors.

18 osition, after acute infection, as part of a paraneoplastic syndrome, and after exposure to neurotoxi

19 Paraneoplastic syndromes are not frequently associated w

20 Melanoma-associated retinopathy (MAR) is a paraneoplastic syndrome associated with cutaneous malign

21 of this review is to define and describe the paraneoplastic syndromes associated with gynecologic neo

22 icion of a paraneoplastic condition, but any paraneoplastic syndrome can also occur in patients witho

23 Some paraneoplastic syndromes can be used as marker of progre

24 ntagonist (VEGF-TRAP(R1R2)), thus defining a paraneoplastic syndrome caused by excessive VEGF activit

25 resistant, upbeat nystagmus resulting from a paraneoplastic syndrome caused by stage 2A, grade I, nod

26 Twenty-four paraneoplastic syndromes have been associated with gynec

27 Paraneoplastic syndromes (i.e. organ/tissue disorders as

28 on the possibility that scleroderma may be a paraneoplastic syndrome in a subset of patients.

29 rapeutic interventions for a group of visual paraneoplastic syndromes, including carcinoma-associated

30 Early diagnosis of paraneoplastic syndromes maximizes the likelihood of a f

31 on that their symptoms or findings reflect a paraneoplastic syndrome may allow the tumor responsible

32 toantibodies or inflammatory gene mutations, paraneoplastic syndrome mechanisms via ectopic cytokine

33 Paraneoplastic syndromes occurring before a cancer diagn

34 eration in normal tissues contributes to the paraneoplastic syndromes of cachexia and anemia.

35 109 small-cell lung cancer patients without paraneoplastic syndromes of the CNS.

36 Most nervous system paraneoplastic syndromes probably result from an immune

37 abnormalities is wide, and include cutaneous paraneoplastic syndromes such as xanthomas, acanthosis n

38 This tumor is associated with unique paraneoplastic syndromes, such as myasthenia gravis, hyp

39 ple sclerosis, neuromyelitis optica, and the paraneoplastic syndromes where highly specific T cell re

40 POEMS syndrome is a paraneoplastic syndrome whose acronym stands for less th

41 Limbic encephalitis is typically a paraneoplastic syndrome with a poor prognosis; thus, ide

42 melanocytic proliferation (BDUMP) is a rare paraneoplastic syndrome with characteristic findings, in

43 Recent work has described paraneoplastic syndromes with prominent, and sometimes i

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。